Strategic Acquisition Catalent's ownership positions Delphi Genetics within a broader CDMO ecosystem, suggesting cross-sell opportunities for Catalent’s GMP and gene therapy services to Delphi’s existing client base and for Delphi’s pDNA capabilities to Catalent’s pharma customers.

pDNA GMP Readiness Delphi is developing GMP facilities for plasmid DNA production, signaling a readiness to scale and partner on gene therapy and DNA vaccine programs; target prospects include companies needing compliant, scalable pDNA manufacture for viral vectors and gene therapies.

Non-Antibiotic Yield The Staby technology enhances recombinant protein and pDNA yields without antibiotics, offering a distinct value proposition for biotech firms seeking high-efficiency production platforms and license or collaboration discussions around stabilization systems.

Antibody & DNA Immunization Delphi’s expertise in DNA immunization and novel antigen presentation for antibody development opens doors to pharma and biotech customers pursuing DNA-based vaccines or innovative antigen delivery approaches.

Strategic Alliances Past partnerships with Alma Biotherapy and Catalent’s acquisition indicate a track record of collaboration; leverage these relationships to propose expanded CDMO engagements, joint development programs, or co-funded projects to accelerate route-to-market timelines.